Secondments

Our PhD fellows, also known as Early Stage Researcher (ESR), will spend some time conducting research activities with associated partners (i.e. secondments).

Scheduled secondments

ESR1a : 1st year, 2 months | 2rd year, 1 month
ESR1b : 2nd year, 3 months
ESR2a : 1st year, 2 months | 2nd year, 1 month
ESR3a : 2nd year, 1.5 months | 3rd year, 1.5 months
ESR4 : 1st year, 3 months
ESR5 : 2nd year, 1 months | 3rd year, 2 months
ESR6 : 2nd year, 1.5 months | 3rd year, 1.5 months
ESR7 : 1st year, 3 months
ESR8 : 2nd year, 3 months
ESR9 : 2nd year, 1.5 months | 2nd year, 1.5 months
ESR10 : 1st year, 3 months
ESR11 : 2nd year, 3 months
  • ESR1a (CNRSa-Rodriguez): i) UNIVDUN, Prof R.T. Hay, to perform MS analysis; ii) Hybrigenics, Dr Jean Christophe Rain, to develop assays to measure interactions UBD-Ubiquitylated proteins.

  • ESR1b (CNRSa-Xirodimas) : LUMCb, Prof H. Ovaa, for the chemical synthesis of NEDD8 chains of defined topology and composition (poly vs. hybrid).

  • ESR2a (MPGa-Pichler) : i) LUMCa, Dr A. Vertegaal, for MS and bioinformatics analysis; ii) UbiQ, Dr F. El Oualid, for the design of ZNF451 inhibitory drugs.

  • ESR3a (LUMCa-Vertegaal) : i) IMB, Prof H. Ulrich, to study a potential role of SUMO-Ub in the DNA damage response; ii) MPGa, Dr A. Pichler, for biochemical analysis of novel SUMO-Ub receptor proteins.

  • ESR3b (LUMCb-Ovaa) : UNIVDUNb, Dr Y. Kulathu, 1st year, 3 months, for structure elucidation of novel (mixed) chains.

  • ESR4 (FMI-Thomas) : Novartis, Dr M. Renatus, 1st year, 3 months, for assay development, compound screening and structure solution of compound-bound protein assemblies.
  • ESR5 (UNILIV-Urbe) : i) LUMCb, Prof H. Ovaa, for generation of chain selective DUB probes; ii) UNIVDUNb, Dr Y. Kulathu, for UbiCREST application.

  • ESR6 (CIC bioGUNE-Barrio): i) LUMCa, Dr A. Vertegaal, for MS analysis; ii) ITAV, Dr M.S. Rodriguez, to validate the results obtained by TUBEs/SUBEs technology.

  • ESR7 (UNIVDUNb-Kulathu) : UNILIV, Dr S. Urbe, on the biological DUB function in mitophagy.

  • ESR8 (GUF-Dikic) : LUMCb, Prof. H. Ovaa, for the development of activity based probes against bacterial E3 ligases.

  • ESR9 (IMB-Ulrich) : i) LUMCa, Dr A. Vertegaal, to collaborate on MS approaches to identify interaction partners of Etp1/BRAP2, ii) UNILIV, Dr S. Urbe, to obtain expertise in mammalian cell culture, CRISPR/Cas9 technology and to collaborate on mechanistic aspects of BRAP2.

  • ESR10 (UNIVDUN-Hay) : LUMCb, Prof H. Ovaa, to learn the principles of chemical synthesis of Ub and SUMO polymers to generate chains of defined length.

  • ESR11 (Novo Nordisk-Nielsen) : LUMCb, Prof H. Ovaa, to develop peptide and protein chemical synthesis tools.